Pursuant to the provisions of Regulations 29 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Hikal has informed that, a meeting of the Board of Directors of the Company is scheduled to be held on Monday, May 29, 2023, to Consider, approve and take on record the audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended on March 31, 2023, alongwith the statements of assets and liabilities and the cash flow statement as on that date, consider, approve and take on record the audited Standalone and Consolidated Financial Statements of the Company for the financial year ended on March 31, 2023 and to recommend payment of final dividend, if any, for the financial year 2022-23, for the approval of shareholders at the 35th Annual General Meeting of the Company.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |